- Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
- Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
- Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
- Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program
- Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration
- Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences
- Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
- Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
More ▼
Key statistics
On Tuesday, Citius Pharmaceuticals Inc (CTXR:NAQ) closed at 0.7673, 27.88% above the 52 week low of 0.600 set on Feb 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.74 |
---|---|
High | 0.7996 |
Low | 0.731 |
Bid | 0.7111 |
Offer | 0.80 |
Previous close | 0.7673 |
Average volume | 1.45m |
---|---|
Shares outstanding | 159.09m |
Free float | 146.79m |
P/E (TTM) | -- |
Market cap | 122.07m USD |
EPS (TTM) | -0.255 USD |
Data delayed at least 15 minutes, as of Apr 23 2024 21:00 BST.
More ▼